Saccharomyces boulardii CNCM I-745 plus sequential therapy for Helicobacter pylori infections: a randomized, open-label trial

Seddik, H.; Boutallaka, H; Elkoti, I.; Nejjari, Fouad; Berraida, R; Berrag, Sanaa; Loubaris, K; Sentissi, Sara; Bourazza, Ahmed

doi:10.1007/s00228-019-02625-0

Cited by 25 publications

(22 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Of these articles, 39 studies were further excluded based on the selection criteria (characteristics of the excluded studies and ongoing trials are presented in Table ). Finally, 18 RCTs(21 intervention arms) met the selection criteria for the meta‐analysis. The PRISMA flowchart of study selection process is presented in Figure .…”

Section: Resultsmentioning

confidence: 99%

“…Among these, three of which were published as conference abstracts . Six of these studies originated from China, four studies from Korea, two from Turkey, one from Italy, one from Romania, one from Greece, one from Iran, one from Thailand, and one from Morocco . Fourteen studies were published in English, and the remaining four studies in Chinese .…”

Section: Resultsmentioning

confidence: 99%

“…Three trials included multiple arms, with a total of 21 intervention arms. With regard to H pylori eradication regimen, fifteen trials used standard triple therapy, two used bismuth‐quadruple therapy, and one used sequential therapy . The duration of eradication regimen ranged from 7 days to 10 days to 14 days.…”

Section: Resultsmentioning

confidence: 99%

“…Three trials were placebo‐controlled. Regarding S boulardii formulations, with the exception of four trials that did not explicitly provide drug form, the remaining probiotics were capsules or sachets. The daily dose of S boulardii was not reported in three trials, and most of the remaining studies ranged from 300 mg to 1000 mg S boulardii were usually administered as an adjuvant for the same duration as the standard eradication therapy, but some trials continued the S boulardii intervention for 4‐21 days.…”

Section: Resultsmentioning

confidence: 99%

“…Among all these studies, ten studies reported sufficient random sequence generation methods (computer‐based random, random number table, or envelope‐drawing system). Only one study provided sufficient data for allocation concealment.…”

Section: Resultsmentioning

confidence: 99%

See 4 more Smart Citations

Saccharomyces boulardii as an adjuvant therapy for Helicobacter pylori eradication: A systematic review and meta‐analysis with trial sequential analysis

Zhou

Chen

et al. 2019

Helicobacter

View full text Add to dashboard Cite

Background and Aims: Whether Saccharomyces boulardii (S boulardii) as an adjuvant therapy are beneficial to H pylori eradication remains controversial. The aim of the study was to update and determine the effects of S boulardii as an adjuvant therapy on H pylori eradication rates and adverse effects. Methods: We searched PubMed, Embase, CENTRAL, and Web of Science to collect all randomized controlled trials assessing the effects of S boulardii as an adjuvant therapy for H pylori eradication from inception to February 2019. Quality of evidence was appraised using Grading of Recommendations, Assessment, Development and Evaluation system. Trial sequential analysis was performed to control the risk of type I and type II errors.Results: Eighteen trials with 3592 patients were eligible for meta-analysis. Compared with standard eradication regimen, the S boulardii supplementation could significantly improve eradication rates [risk ratio (RR) = 1.09, 95% confidence interval (CI):1.05-1.13; moderate quality evidence] and reduce the incidence of total side effects (RR = 0.47, 95%CI:0.36-0.61; low quality evidence), as well as some gastrointestinal adverse effects, especially diarrhea (RR = 0.33, 95%CI:0.23-0.47; low quality evidence) and constipation (RR = 0.37, 95%CI:0.23-0.57; moderate quality evidence).In addition, the need for discontinuation rate in S boulardii supplementation group was significantly lower than in the control group (RR = 0.33, 95%CI:0.16-0.69, P = .003; moderate quality evidence). The TSA results for overall eradication rates and total side effects indicated that the effects were conclusive. Conclusions:Our meta-analysis shows that S boulardii supplementation on standard eradication therapy significantly increased H pylori eradication rates and reduced the incidence of total side effects and some gastrointestinal adverse effects during eradication therapy. K E Y W O R D SHelicobacter pylori, meta-analysis, Saccharomyces boulardii, trial sequential analysis 2 of 16 | ZHOU et al.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Saccharomyces boulardii as an adjuvant therapy for Helicobacter pylori eradication: A systematic review and meta‐analysis with trial sequential analysis

Zhou

Chen

et al. 2019

Helicobacter

View full text Add to dashboard Cite

show abstract

Probiotics

Kim,

Hwang

2023

Helicobacter Pylori

View full text Add to dashboard Cite

The impacts of probiotics in eradication therapy of Helicobacter pylori

Bai

Zhu

et al. 2022

Arch Microbiol

View full text Add to dashboard Cite

Helicobacter pylori (H. pylori) is a well-known pathogen that infects approximately half of the world’s population. It is a pathogenic agent with potential health hazards related to diverse diseases, especially digestive diseases, such as chronic gastritis, peptic ulcer, and gastric carcinoma. In clinical, antibiotics are commonly applied in eradication therapy of H. pylori. However, the increase in antibiotic resistance and side effects has induced the failure of eradication therapy. Recent studies have shown that probiotic supplementation has promising application prospects. It can restore the gastrointestinal microbiota balance and prevent dysbacteriosis caused by antibiotics. Furthermore, it has been reported to have direct or indirect inhibitory effects on H. pylori. Probiotics may have a beneficial effect on H. pylori eradication. However, the strain, dosages, duration times, and safety of probiotic supplementation need further study before clinical applications.

show abstract

Saccharomyces boulardii CNCM I-745 plus sequential therapy for Helicobacter pylori infections: a randomized, open-label trial

Cited by 25 publications

References 33 publications

Saccharomyces boulardii as an adjuvant therapy for Helicobacter pylori eradication: A systematic review and meta‐analysis with trial sequential analysis

Saccharomyces boulardii as an adjuvant therapy for Helicobacter pylori eradication: A systematic review and meta‐analysis with trial sequential analysis

Probiotics

The impacts of probiotics in eradication therapy of Helicobacter pylori

Contact Info

Product

Resources

About